Introduction

Lung diseases are among the most prominent pathologies around the world because of their considerable impact on the population. As the Centers for Disease Control and Prevention reports, chronic lower respiratory diseases constitute the third leading cause of death in the U.S., with more than 140,000 people dying of such diseases in 2011 (1). Additionally, acute respiratory distress syndrome (ARDS) is the leading cause of death in the intensive care population, with mortality rates between 40 and 60% (2). Furthermore, progressive and irreversible lung diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disorder (COPD) lack any definitive treatment other than lung transplantation (3). However, the need for transplants far surpasses low donor availability, and each transplant carries risks of rejection for the patient; only about 50% of lung transplant recipients survive to five years (4).

Non-cancerous lung diseases inhibit normal breathing through the development of fibrosis in the lung tissue or inflammation of airways or general parenchyma, and they include diseases such as COPD, IPF, and ARDS as well as asthma, obstructive sleep apnea, and bronchiolitis obliterans. Obstruction or restriction of the airways causes an increase in airflow resistance or decrease in compliance. Chronic injuries interfere with the healing process that enhances tissue remodeling and fibrosis, increasing the scarring and extracellular matrix components, contributing in that way to the loss of lung function (5, 6).

The need for new options is critical, and cell therapy is one of the most promising tools for treatment of lung diseases. Although many properties and mechanisms of action of various types of stem cells are known, details regarding their migration throughout the injured body and their survival mechanisms at the injured tissue are not yet completely understood. Nevertheless, treatment with stem cells constitutes a very good option for patients who would otherwise have to rely on transplantation. The promise of stem cells – specifically, mesenchymal stem cells – in lung diseases will be the subject of this review. The ability of these cells to participate in lung tissue repair through interaction with stromal and inflammatory cells at the injured tissue makes them an undeniable component to the future of lung disease research.

KEY WORDS: mesenchymal stem cells, lung disease, cell therapy, aging, clinical trials.
Identification of Mesenchymal stem cells

Mesenchymal stem cells (MSCs) are key for tissue repair and regeneration due to their unlimited self-renewal, capacity for clonality, and ability to differentiate in vitro into various specialized cell types that include cartilage, tendon, bone, and adipose tissue (5, 7). Thus, MSCs have been identified as key in the management of different chronic pathologies, like type 1 diabetes, graft-versus-host disease, and inflammatory bowel disease (6), and their effects on lung diseases are currently being studied in animal models and clinical trials. Categorized by origin, MSCs are somatic stem cells. However, the precise characterization of MSCs has been difficult due to the lack of specific surface markers. However, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy has set minimal criteria to define human MSCs: MSCs when cultured in standard conditions have to be plastic-adherent; they must express adhesion and stromal markers such as CD44, CD105, CD73, and CD90 and lack expression of hematopoietic markers CD45, CD34, CD31, CD14, CD11b, CD19, and CD97α; and the cells must have the ability to differentiate in vitro to chondrocytes, adipocytes, and osteoblasts (8). MSCs have fibroblast-like morphology, so a challenge in selection has been the distinction between MSCs and fibroblasts in culture. Although MSCs share the same markers and have a spindle shape as fibroblasts do, the main characteristic for distinguishing them is the ability of MSCs to forming colonies and the fact that MSCs are multipotent with the ability of self-renewal, whereas fibroblasts are terminally differentiated cells (9). However, a standard is still lacking to completely distinguish both cell types. Additionally, the presence of lung-resident stem cells that act as progenitor cells during the response to epithelial injury (10) has led some to contemplate the use of lung-resident stem cells as a treatment option in addition to MSCs. Lung-resident stem cells are specialized cells that reside in their own niche within the lung tissue and have the ability to differentiate into specialized cells of the organ. However, due to the high number of cell types that the lung has (more than 40), it has been difficult to recognize the progenitor cells. Some investigations have highlighted type II alveolar epithelial cells, basal cells, and Clue cells as important cells with progenitor functions (11, 12). Type II alveolar epithelial cells are essential for maintaining the pulmonary epithelium, but this epithelium has a lower capacity for regeneration and turnover compared to other organs such as skin, making the work of lung resident stem cells insufficient in combating an injury (11-13).

The recent discovery (14) of self-renewing, clonogenic, multipotent lung stem cells with the ability to form distal airways and pulmonary vessels has exciting implications for clinical application. These cells would certainly be ideal for therapy in the damaged lung, but the novelty of this discovery means that little is known about lung stem cells so more investigation is needed. Additionally, there has been special attention paid to the potential use of induced pluripotent stem cells in lung diseases, but these and progenitor cells will not fall under the scope of this review.

Mechanisms of action of MSCs

It is thought that due to the close relationship between the lung epithelium and the stromal tissue, MSCs may play a role in the maintenance of the epithelium (6). Although some mechanisms are still being investigated, a number of studies have supported the role of MSCs in immunomodulation and the anti-inflammatory response. Mechanisms that include cell-cell contact and secretion of mediators (15) may play a key role in tissue regeneration due to the ability of MSCs to induce T-cell apoptosis that triggers macrophages to increase levels of TGF-β (16). Additionally, MSCs secrete IL-10, suppressing T-cell responses and inducing regulatory T-cells and thus, promoting mucosal tolerance (17). Growth factors secreted by the MSCs that are generated through inflammatory stimuli activate the immunosuppressive capacity of MSCs. Additionally, MSCs secrete chemokine and adhesion molecules that act in a synergistic manner with substances like nitric oxide or indoleamine 2,3 dioxygenase to suppress the immune system (6), and they can further protect against acute lung injury by secreting microvesicles that contain mitochondria, which are transferred to the alveolar epithelium (18). The application of these effects to different lung diseases is shown in Figure 1.

Other properties of MSCs

Another crucial property of MSCs is the low expression of HLA I and HLA II, which provide poor immunogenicity (10), causing MSCs to avoid the cytotoxic T cells and natural killer cells. This confers to MSCs a form of immunoprivilege and with it, the ability to be transplanted without generating an immune response in patients with a competent immune system (15). However, these properties are lost with differentiation (19). The ability of MSCs to contribute to the restoration of injured tissue has been proven not only by their im-
Mesenchymal stem cells in lung diseases

Munomodulatory and anti-inflammatory properties, but also by their capacities for mitochondrial transfer, as mitochondrial dysfunction constitutes an important facet of apoptosis, cellular senescence, and cell proliferation. Islam et al. proved that ATP concentration in the host pulmonary alveoli increases after the instillation of MSCs, contributing to energetic restoration and protection in the acute phase of lung injury, and supporting the presence of mitochondrial transfer from the MSC to the host cell in a lipopolysaccharide acute lung injury model (18).

The amelioration of lung injury has been demonstrated by our group through several murine models of injury. We evaluated the functions of bone marrow-derived MSCs in myelosuppressed and normal mice and showed that in a bleomycin model, only one third of the immunosuppressed mice survived after 14 days. However, after administration of MSCs six hours after the lung injury there was a 100% rate of survival, and the lung injury was minimal in the immunocompetent mice. We also showed that with MSC administration, the levels of G-CSF and GM-CSF increased, causing mobilization of stem cells from pools (20).

We have also demonstrated the ability of MSCs to migrate to the injured lung. By using a pore membrane and fluorescence microscopy, we culturing mice lung cells with green fluorescent protein and MSCs after a single dose of LPS or saline. The results obtained showed migration of MSCs toward the cell suspensions (16).

Aging and MSCs

Because the incidence of both acute diseases such as ARDS and chronic diseases such as COPD and IPF increases with age, a special interest has emerged in the study of aging and its relation not only to these pathologies but also to the use of MSCs as therapy (21).

Some elements present in normal processes of aging, such as oxidative stress and abnormal telomere shortening, are important deleterious effects of tobacco smoking on pulmonary parenchyma (3, 22). It is well known that an appropriate telomere length is crucial for the survival of stem cells, and this has been supported by the expression of telomerase in type II alveolar epithelial cells following alveolar damage (22).

Other factors in aging include changes in the composition of the extracellular matrix and changes related to the decrease in cardiac output that contribute to lower arterial PO2 and loss of lung volume. All these factors, associated with a decrease in the adrenergic control of cardiovascular function according to normal aging, lead to a decrease in the response to sepsis and might affect the migration of MSCs to the injured tissue (21).

Figure 1 - MSCs have a variety of effects on lung diseases including secretion of growth factors, cytokines, and microvesicles.
MSCs in acute lung diseases

ARDS has a prevalence estimated at 22% and an in-hospital mortality close to 40% (25), making it the leading cause of death for intensive care unit patients (2). Lung conditions and systemic diseases that affect the lung through the bloodstream are associated with the development of ARDS, and the disease encompasses an increase in alveolar and vascular permeability (mediated by endothelin-1, phospholipase A2, and angiotensin-2), loss of epithelial integrity, influx of inflammatory cells (IL-1β, TNF-α, and IL-6), and formation of hyaline membranes in a complex process that frequently ends in multiple organ failure as a cause of death (16).

The Berlin definition (26) set the new diagnosis criteria for ARDS based on: timing (within one week of clinical insult or new or worsening respiratory symptoms), radiography (bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules), origin of edema (respiratory failure not fully explained by cardiac failure or fluid overload), and oxygenation impairment (mild: 200 mmHg < PaO2/FiO2 <300 mmHg, moderate: 100 mmHg < PaO2/FiO2 200 <300 mmHg, and severe: PaO2/FiO2 <100 mmHg). Thus, according to this definition, the term “acute lung injury” as used previously now falls in the category of moderate ARDS (16, 26).

Despite the increased interest in reaching a curative treatment for this condition, the current therapies focus on supportive care techniques of lung protective ventilation and a conservative fluid strategy (27), and there is not a proven therapy to reduce the severity of lung injury or to improve the outcomes. Thus, the literature has focused on different options that contribute to tissue repair – not only to support of injured lungs – opening in this way an opportunity for the therapeutic use of MSCs.

Different studies have demonstrated the proliferative potential of MSCs through the secretion of cytokines and growth factors using murine (28) and large animal (29, 30) models of endotoxin-induced ARDS. These experiments revealed a decrease in proinflammatory cytokines, increase in anti-inflammatory cytokines, histological decrease in lung injury, and overall increase in survival rates (16, 20, 28-34). Our group has demonstrated that infusion of MSCs prevents the inflammatory response to endotoxin and attenuates the lung injury, protecting as well against pulmonary edema (7). Furthermore, MSCs regulate the inflammatory signaling process in injured lung cells by decreasing IL-1β, TNF-α, and IL-6 among others (7, 33). To improve MSC efficacy, the cells can be preactivated in vitro through stimulation with serum from ARDS patients. In a murine model, use of activated MSCs resulted in reduced histological lung inflammation scores and lung vascular permeability as well as decreased levels of inflammatory cells compared with treatment with non-stimulated MSCs (35).

MSCs in chronic lung diseases

**Chronic pulmonary obstructive disease**

Chronic pulmonary obstructive disease (COPD) is the third leading cause of death worldwide (36) with smoking as the principal preventable risk factor. Emphysema, characterized by a loss of alveolar architecture, is a key component present in COPD, and although the pathogenesis of emphysema is still unclear (37), inactivation of vascular endothelial growth factor (VEGF) is crucial in the development of this condition (38). MSCs act in the emphysematous lung through suppression of apoptosis (39, 40), down-regulation of proinflammatory cytokines TNF-α, IL-1, and IL-6, and upregulation of VEGF and TGFβ-1 (40). In a clinical trial recently conducted by Weiss et al., 62 patients were given doses of either allogeneic MSCs or a placebo, demonstrating the safety of cell therapy for COPD. A decrease in the C-reactive protein in the MSC treatment suggests a role for MSCs in the modulation of the inflammatory pathway. However, there were not significant differences in pulmonary function test or quality of life, so future investigations should be forthcoming (41, 42).

**Idiopathic pulmonary fibrosis**

Idiopathic pulmonary fibrosis (IPF), the most common type of interstitial lung disease, is irreversible, progressive, and has a poor prognosis. The prevalence is around 27.9 cases per 100,000 inhabitants, increasing with age, and the prevalence is greater among males than females (43). The complete understanding of the pathogenesis of IPF still remains uncertain; however, an abnormal activation of regenerative processes has been implicated by the increase in the deposition of fibroblasts and myofibroblasts (22).

Different bleomycin models in mice have been conducted, including studies from our group, where early treatment with MSCs has shown reductions in collagen deposition and expression of matrix metalloproteinases 2 and 9, decreases in epithelial damage, and improved survival rates (20, 31, 44, 45). Confidence in the use of MSCs as therapy for IPF patients has progressed to the clinical trial phase, with one completed phase I trial and several in the recruiting stage (clinicaltrials.gov).

**Bronchiolitis obliterans**

Bronchiolitis obliterans (BO) is one of the main concerns...
in pulmonary transplantation because of the poor prognosis that it entails, affecting around 50% of all the lung transplant recipients, with a mean survival time of 3 years (46). It is believed to be a form of chronic rejection in which management with high doses of immunosuppressive agents seems to be the only available therapy, even accounting for the deleterious effects often observed with the use of these agents (47). BO is characterized by the presence of a patchy submucosal fibrosis involving the respiratory bronchioles, which leads to obliteration of the distal airways by inflammatory infiltrates, fibroblasts, collagen, and matrix deposition. The damage to the airways and decrease in the total surface area for gas exchange induces chronic pulmonary dysfunction (47, 48). Although the complete mechanisms that participate in this pathology are not fully understood, fibrocytes are thought to play a key role, so they may be useful as a marker in future studies (49).

The beneficial effects of MSCs seen with diseases other than lung pathologies suggests that they may be beneficial in treating BO. In a mouse model of heterotopic tracheal transplantation, our group demonstrated the positive effects by bone marrow-derived MSCs on the attenuation of airway obliteration (28), and another group has demonstrated a similar protective effect by placenta-derived MSCs in the heterotopic tracheal transplantation (50). In murine orthotopic tracheal transplantation, MSCs protected as well against allograft rejection, further supporting the promising role of stem cells in BO (51).

**Asthma**

The World Health Organization estimates that 235 million people worldwide currently suffer from asthma (52), and the allergen-driven disease is a likely target of therapy by MSC immunomodulation. Asthma is characterized by inflammation and hyperresponsiveness of the airway, and airway wall remodeling includes epithelial injury, thickening of the reticular basement membrane, and increases in airway smooth muscle mass (53). Attenuation of asthmatic injury by MSCs will likely come through immunological mechanisms, rather than engraftment in the lung airway or alveolar epithelium, which is a rare occurrence (54). Several studies have shown the efficacy of MSC use in animal models of asthma and support the anti-inflammatory mechanisms of the cells. In a murine ovalbumin model of chronic asthma, IL-5, IL-13, IgE, and iNOS were all decreased, as were eosinophil levels (55). In a murine ragweed model, airway mucus and eosinophil levels were decreased, and IL-4 and IL-13 levels were reduced by treatment with MSCs (56). The study also showed that the MSC-treated animals recruited more anti-inflammatory regulatory T cells to the lungs.

**Obstructive sleep apnea**

Obstructive sleep apnea (OSA) is a breathing disorder in which increased upper airway collapsibility leads to recurrent intrathoracic pressure swings and hypoxia. The recurrent apneas disrupt normal sleep patterns, and the oxidative stress and inflammation induced by hypoxia can have long-term effects of hypertension, ischemia, cerebrovascular disease, and heart failure (57). The research on MSCs is limited, but Carreras et al. have shown that in a rat model of OSA, the recurrent apneas caused early release of MSCs into the circulating blood (58), that the MSCs had higher mobility and increased adhesion to endothelial cells (59), and that MSCs contributed to the anti-inflammatory response prompted by the inflammation of the disease by decreasing levels of IL-1β (60). In a study that found that OSA induces atrial fibrosis, treatment with MSCs was also found to prevent the increase in IL-1β (61). The greatest benefit of MSC therapy in OSA, then, appears to be the anti-inflammatory effect that can counter the damaging inflammation of the obstructed airways.

**Conclusion**

It is clear that MSCs are a promising therapy for lung diseases. The success of preclinical animal studies has proven the ameliorating effects on MSCs on a number of lung diseases, through mechanisms that include decreasing levels of pro-inflammatory cytokine, suppressing apoptosis, and secreting growth factors and mitochondria. Studies to better understand the aspects that still remain unknown are ongoing and will contribute to future treatment options. As clinical trials progress in COPD and IPF, we will soon know more about this potentially life-saving therapy.

**References**


